Grandview Asset Management LLC lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 5.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 12,342 shares of the company’s stock after selling 665 shares during the quarter. Johnson & Johnson makes up approximately 1.4% of Grandview Asset Management LLC’s investment portfolio, making the stock its 15th largest position. Grandview Asset Management LLC’s holdings in Johnson & Johnson were worth $2,180,000 at the end of the most recent quarter.
Other institutional investors have also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD boosted its holdings in shares of Johnson & Johnson by 18.9% during the second quarter. Price T Rowe Associates Inc. MD now owns 24,622,795 shares of the company’s stock worth $4,370,793,000 after acquiring an additional 3,912,430 shares during the period. FMR LLC boosted its holdings in shares of Johnson & Johnson by 20.8% during the second quarter. FMR LLC now owns 18,725,049 shares of the company’s stock worth $3,323,883,000 after acquiring an additional 3,229,032 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Johnson & Johnson by 1.2% during the third quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock worth $40,078,885,000 after acquiring an additional 2,815,655 shares during the period. GQG Partners LLC boosted its holdings in shares of Johnson & Johnson by 64.4% during the first quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock worth $1,151,931,000 after acquiring an additional 2,547,378 shares during the period. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its holdings in shares of Johnson & Johnson by 52.2% during the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 6,102,999 shares of the company’s stock worth $1,083,329,000 after acquiring an additional 2,093,392 shares during the period. Institutional investors and hedge funds own 67.94% of the company’s stock.
Wall Street Analyst Weigh In
Several equities research analysts recently issued reports on the company. Piper Sandler cut their price target on Johnson & Johnson from $55.00 to $52.00 in a research note on Monday, February 6th. SVB Leerink cut their price target on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a research note on Friday, January 20th. Morgan Stanley boosted their price target on Johnson & Johnson from $176.00 to $180.00 and gave the company an “equal weight” rating in a research note on Wednesday, January 25th. Citigroup boosted their price target on Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a research note on Monday, December 12th. Finally, StockNews.com began coverage on Johnson & Johnson in a research note on Thursday. They set a “strong-buy” rating for the company. Seven analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $174.73.
Insider Activity at Johnson & Johnson
Johnson & Johnson Stock Down 1.1 %
Shares of NYSE:JNJ opened at $152.38 on Friday. The company has a fifty day moving average of $161.97 and a 200-day moving average of $167.88. The company has a market capitalization of $396.84 billion, a PE ratio of 22.61, a price-to-earnings-growth ratio of 2.65 and a beta of 0.54. The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.77 and a current ratio of 0.99. Johnson & Johnson has a 52-week low of $150.71 and a 52-week high of $186.69.
Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.22 by $0.13. The company had revenue of $23.71 billion during the quarter, compared to the consensus estimate of $23.90 billion. Johnson & Johnson had a net margin of 18.90% and a return on equity of 35.76%. The company’s revenue for the quarter was down 4.4% compared to the same quarter last year. During the same period in the prior year, the business earned $2.13 earnings per share. On average, equities analysts predict that Johnson & Johnson will post 10.5 EPS for the current fiscal year.
Johnson & Johnson Dividend Announcement
The business also recently declared a quarterly dividend, which was paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st were issued a dividend of $1.13 per share. The ex-dividend date was Friday, February 17th. This represents a $4.52 annualized dividend and a dividend yield of 2.97%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 67.06%.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.